VAXX vs. EYEN, RVPH, VYNE, FBIO, LPCN, MRKR, PMN, XLO, CARA, and UNCY
Should you be buying Vaxxinity stock or one of its competitors? The main competitors of Vaxxinity include Eyenovia (EYEN), Reviva Pharmaceuticals (RVPH), VYNE Therapeutics (VYNE), Fortress Biotech (FBIO), Lipocine (LPCN), Marker Therapeutics (MRKR), ProMIS Neurosciences (PMN), Xilio Therapeutics (XLO), Cara Therapeutics (CARA), and Unicycive Therapeutics (UNCY). These companies are all part of the "pharmaceutical preparations" industry.
Eyenovia (NASDAQ:EYEN) and Vaxxinity (NASDAQ:VAXX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, community ranking, valuation and profitability.
Eyenovia received 165 more outperform votes than Vaxxinity when rated by MarketBeat users. Likewise, 65.13% of users gave Eyenovia an outperform vote while only 38.46% of users gave Vaxxinity an outperform vote.
Eyenovia currently has a consensus price target of $10.00, suggesting a potential upside of 1,137.62%. Vaxxinity has a consensus price target of $7.00, suggesting a potential upside of 8,839.97%. Given Eyenovia's higher probable upside, analysts clearly believe Vaxxinity is more favorable than Eyenovia.
Eyenovia's return on equity of -192.58% beat Vaxxinity's return on equity.
25.8% of Eyenovia shares are owned by institutional investors. Comparatively, 83.0% of Vaxxinity shares are owned by institutional investors. 7.1% of Eyenovia shares are owned by company insiders. Comparatively, 64.1% of Vaxxinity shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Eyenovia has higher earnings, but lower revenue than Vaxxinity. Eyenovia is trading at a lower price-to-earnings ratio than Vaxxinity, indicating that it is currently the more affordable of the two stocks.
Eyenovia has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500. Comparatively, Vaxxinity has a beta of 2.79, suggesting that its share price is 179% more volatile than the S&P 500.
In the previous week, Eyenovia had 2 more articles in the media than Vaxxinity. MarketBeat recorded 2 mentions for Eyenovia and 0 mentions for Vaxxinity. Vaxxinity's average media sentiment score of 1.43 beat Eyenovia's score of 0.00 indicating that Eyenovia is being referred to more favorably in the media.
Summary
Vaxxinity beats Eyenovia on 9 of the 15 factors compared between the two stocks.
Get Vaxxinity News Delivered to You Automatically
Sign up to receive the latest news and ratings for VAXX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VAXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vaxxinity Competitors List
Related Companies and Tools
